Physician profile
Frederick A Gulmi
NPI 1588652838
$2,404.32
in general payments reported to CMS, 2019-2025
23 companies · $617 in 2025
The $617 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $13.86 · 2021: $59.70 · 2022: $366 · 2023: $93.49 · 2024: $361 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $772.27 | 2019-2024 | Aquabeam System |
| Sumitomo Pharma America, INC. | $235.29 | 2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $233.10 | 2019-2022 | |
| Richard Wolf Medical Instruments Corp. | $145.85 | 2019 | |
| Calyxo, INC. | $137.67 | 2025 | Cvac Aspiration System |
| Neotract INC. | $127.09 | 2019 | |
| Urogen Pharma, INC. | $92.32 | 2023-2025 | Jelmyto |
| Civco Medical Instruments | $89.75 | 2025 | |
| Axonics, INC. | $76.27 | 2022-2023 | Axonics |
| Merck Sharp & Dohme LLC | $72.55 | 2023-2024 | Keytruda |
| Genmab U.S., INC. | $55.68 | 2023-2024 | Tivdak |
| Photocure INC | $53.03 | 2024 | Cysview |
| Travere Therapeutics, INC. | $49.97 | 2019 | |
| Hitachi Healthcare Americas Corp. | $44.29 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $41.84 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.86 | 2020-2021 | |
| Astellas Pharma US INC | $24.71 | 2025 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $24.47 | 2022 | |
| Ferring Pharmaceuticals INC. | $23.05 | 2024 | Adstiladrin |
| Janssen Biotech, INC. | $21.29 | 2024 | Akeega, Balversa, Erleada |
| Tolmar, INC. | $19.23 | 2025 | Jatenzo |
| Seqirus USA INC | $16.34 | 2025 | Fluad, Flucelvax |
| Laborie Medical Technologies Corp. | $13.40 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Gulmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.